OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis

ABSTRACT: Background: Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in...

Full description

Autores:
Buendía Rodríguez, Jefferson Antonio
Lindarte Rincón, Erika Fernanda
Guerrero Patiño, Diana
Tipo de recurso:
Article of investigation
Fecha de publicación:
2022
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/45374
Acceso en línea:
https://hdl.handle.net/10495/45374
Palabra clave:
Niño
Child
Colombia
Análisis Costo-Beneficio
Cost-Benefit Analysis
Infecciones del Tracto Respiratorio
Respiratory Tract Infections
Economía y Organizaciones para la Atención de la Salud
Health Care Economics and Organizations
Corticoesteroides
Adrenal Cortex Hormones
https://id.nlm.nih.gov/mesh/D002648
https://id.nlm.nih.gov/mesh/D003105
https://id.nlm.nih.gov/mesh/D003362
http://id.nlm.nih.gov/mesh/D012141
https://id.nlm.nih.gov/mesh/D004472
https://id.nlm.nih.gov/mesh/D000305
Rights
openAccess
License
http://creativecommons.org/licenses/by/2.5/co/
Description
Summary:ABSTRACT: Background: Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in children. Methods: A decision tree model was used to estimate the cost and quality-adjusted life-years (QALYs) of OM-85 BV in a patient aged 1-6 with a history of recurrent respiratory tract infections. Multiple sensitivity analyses were conducted to evaluate the robustness of the model. Cost-effectiveness was evaluated using the willingness-to-pay defined for Colombia of US$5180 per QALY. The time horizon defined was six months. Costs were estimated from a societal perspective. Results: The expected annual cost per patient with OM-85 BV was US$843 and with placebo was US$1167. The QALYs per person estimated with OM-85 BV was 0.91 and with placebo was 0.89. Conclusion: In conclusion, our study shows that OM-85 BV is a cost-effective strategy to reduce the incidence of recurrent respiratory tract infections in children. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines.